222. Primary nephrotic syndrome Clinical trials / Disease details
Clinical trials : 285 / Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01845688 (ClinicalTrials.gov) | November 2011 | 29/4/2013 | Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy | Efficacy and Safety Evaluation of QingReMoShen Granule in the Treatment of Idiopathic Membranous Nephropathy : A Randomized Double-Blind Controlled Clinical Study | Idiopathic Membranous Nephropathy | Drug: Losartan Tablets & QingReMoShen Granule;Drug: Losartan Tablets & Placebo Granule | wanglin | NULL | Active, not recruiting | 18 Years | 70 Years | Both | 72 | N/A | China |